Differences in cost of treatment mostly depend on labor costs, use of technology, cost of medication and length of hospital stay, although relative weight of these factors may differ from country to country. In any case, the most significant proportion of direct costs (60%) is related to hospital care. 4 It has to be emphasized that there is no simple relationship between the level of investment in health-care and the outcome. For example, in-hospital cost of bypass surgery in the USA is twice as high as in Canada. This difference is not explained by demographic or clinical differences, and does not result in a better clinical outcome. 5 Within the EU, where both the burden of CVD and the economical potential differ among member countries, medical needs must be met in the environment of cost containment. The attempts aimed at optimization of investment in cardiovascular care should be addressed on both European and national level. We need to draw a full picture of CVD impact on the EU population, that would include comprehensive health statistics, data on therapy and prevention, clinical outcome and, finally, direct and indirect economic burdens of CVD. While reliable data on health statistics are now available, 1 other components are only developing. National CVD databases have been or are being developed in several European countries. National audit tools are complemented by a comprehensive Euro Heart Survey programme offered by the European Society of Cardiology. The ideal scenario for the future is to merge all available national databases, and fill the existing gaps by pan-European surveys. Adoption of the Cardiology Audit and Data Standards by all EU countries is a sine qua non for effective comparison of data coming from different countries. 6 It has been well proved that the best clinical outcome can be achieved if patients are treated according to guidelines. 7 In some countries strict adherence to those guidelines requiring application of high technology in a large number of patients proves increasingly difficult, although to some extent technology cost may be compensated by low medical personnel fees. Each country then needs to decide what is the best individual investment strategy to meet medical needs. Obviously, these attempts should be focused not only on the treatment, but also on the prevention of CVD. 8 In addition to studying the costs of medical care, it may be interesting to follow the relationship between the investment outside the health sector, such as & The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
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those related to lifestyle changes, on subsequent benefits within this sector.
Learning from the experience of others could be of great help in the decision-making process on the national level. However, comparison of health-related expenditures between different countries proves to be a challenge, mostly because of the lack of comprehensive data. 4 It is in the best interest of the EU citizens to have these data available as soon as possible.
The paper by Leal et al. 4 is important for several reasons. While it is the first comprehensive source of information on the economic burden of CVD in the EU, it also exposes all gaps and inadequacies in existing data collection systems, and calls for a concerted research effort to make better use of the existing financial resources to meet the challenges of CVD epidemics. This important study should be of interest to health-care providers and research funding organizations in Europe.
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